InsidersTradesSigma
Follow the Palisade Bio, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Palisade Bio, INC. has published 71 reports. Market capitalisation: €355.5m. The latest transaction was disclosed on 21 August 2026 (Don). Among the most active insiders: Finley John David. Every trade is free.
71
Insider Decl.
n/a
Thresholds
€382,008
27 ops.
Buy Volume
€358,292
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Palisade Bio, INC. Strong Buy (bullish), based on 9 analysts. Average price target: US$10.22.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations71 total
88,400 shares0Common StockSEC:0001493152-26-039746:0
88,400 shares0Common StockSEC:0001493152-26-039746:1
20,000 shares@ US$1.98990.012% mcap15.9% of flowCommon StockSEC:0001493152-26-032884:0
Canonical exit: 6 Oct 2026 (T+90)
25,000 shares@ US$1.9560.015% mcap19.5% of flowCommon StockSEC:0001493152-26-032884:1
Canonical exit: 7 Oct 2026 (T+90)
146,798 shares@ US$2.06640.086% mcap43.3% of flowCommon StockSEC:0001493152-26-032559:1
335,167 sharesCommon StockSEC:0001493152-26-032559:0
131,167 sharesCommon StockSEC:0001493152-26-032561:0
20,000 shares@ US$2.0520.011% mcap25.4% of flowCommon StockSEC:0001493152-26-032563:0
Canonical exit: 4 Oct 2026 (T+90)
30,000 shares@ US$2.03480.017% mcap37.7% of flowCommon StockSEC:0001493152-26-032563:1
Canonical exit: 5 Oct 2026 (T+90)
133 shares@ US$0.700.0000% mcap0.0% of flowCommon StockSEC:0001493152-26-032559:2
51,880 shares@ US$2.05350.029% mcap100.0% of flowCommon StockSEC:0001493152-26-032561:1
146,798 shares@ US$2.06640.093% mcap43.3% of flowCommonSEC144:0001974078-26-000266
53,000 shares@ US$2.040.033% mcap50.4% of flowCommonSEC144:0001974078-26-000267
20,000 shares@ US$1.980.011% mcap66.8% of flowCommon StockSEC:0001493152-26-032229:0
Canonical exit: 29 Sept 2026 (T+90)
10,000 shares@ US$1.980.0054% mcap33.2% of flowCommon StockSEC:0001493152-26-032229:1
Canonical exit: 30 Sept 2026 (T+90)
336,904 sharesCommon StockSEC:0001493152-26-029329:0
592,300 sharesCommon StockSEC:0001493152-26-028570:0
20,200 sharesCommon StockSEC:0001493152-26-028570:1
8,000 sharesCommon StockSEC:0001493152-26-006833:0
13,333 sharesCommon StockSEC:0001493152-26-006831:0
5,000 shares@ US$1.671220.2% of flowCommon StockSEC:0001493152-26-003078:0
Canonical exit: 16 Apr 2026 (T+90)
5,000 shares@ US$1.8822.6% of flowCommon StockSEC:0001493152-26-002107:0
Canonical exit: 9 Apr 2026 (T+90)
388 shares0Comon Stock, par value $0.01SEC:0001493152-24-047363:0
388 shares0Comon Stock, par value $0.01SEC:0001493152-24-047364:0
465 shares0Comon Stock, par value $0.01SEC:0001493152-24-023614:0
25 of 71 declarations
关于 Palisade Bio, INC.
Palisade Bio, Inc. (纳斯达克: PALI) 是一家临床阶段的生物制药公司，总部位于美国加利福尼亚州卡尔斯巴德，并在纳斯达克资本市场上市。对于投资者而言，该公司是一个高度专注的开发故事，而非多元化的商业生物技术公司。其核心战略围绕着一个以PDE4生物学为中心的差异化口服前药平台，旨在改善慢性炎症和纤维化疾病患者的耐受性、药理学和便利性。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001357459/000135745926000004/pali-20251231.htm?utm_source=openai)) 该公司的主要资产是PALI-2108，一种每日一次的口服PDE4抑制剂前药，旨在选择性地在末端回肠和结肠中激活。该项目的逻辑是将活性集中在疾病部位，同时限制全身暴露，这可能有助于减少历史上限制PDE4疗法的与类别相关的中枢神经系统和胃肠道副作用。Palisade Bio披露的开发重点是炎症性肠病，特别是溃疡性结肠炎和纤维狭窄性克罗恩病，该平台概念可能扩展到其他炎症和纤维化适应症。([palisadebio.com](https://palisadebio.com/about-us-overview/?utm_source=openai)) 在竞争方面，Palisade Bio 符合小型美国生物技术公司的特征，其估值主要由临床数据、监管里程碑和资金执行驱动。该公司尚未拥有商业产品基础或有意义的经常性运营收入；相反，其投资案例取决于PALI-2108是否能展示出引人注目的疗效/安全性特征，并与现有IBD治疗方法有明显区别。这使得纳斯达克股票对试验结果、方案更新和融资活动特别敏感。([palisadebio.com](https://palisadebio.com/pipeline-overview/?utm_source=openai)) 公司近期更新具有建设性。在2025年和2026年，Palisade Bio 报告了PALI-2108的积极的1a期和1b期结果，包括纤维狭窄性克罗恩病和溃疡性结肠炎的额外顶线数据。最新的季度更新还强调了持续的临床进展和预计在2026年启动的2期试验，表明管理层正试图将主要项目从概念验证阶段推进到后期开发。对于在美国上市的纳斯达克股票投资者而言，这个故事仍然是一个经典的临床催化剂管线：如果执行持续，则有很高的上行空间，但也存在开发阶段生物技术公司典型的较高二元风险。([palisadebio.com](https://palisadebio.com/palisade-bio-reports-first-quarter-2026-financial-results-and-highlights-continued-clinical-progress-of-pali-2108/?utm_source=openai))
